Nature Medicine - In a systematic review and meta-analysis of nonrelapse mortality (NRM) following CAR T cell treatment in 7,604 patients with lymphoma and myeloma, almost half of cases were...

TO THE EDITOR:

Although chimeric antigen receptor (CAR) T cell therapy (CAR-T) has altered the treatment landscape for relapsed/refractory B cell malignancies and multiple myeloma, only a minority of patients...

Post CAR-T neutrophil recovery phenotypes impact survival and reflect CAR expansion kinetics and serum proteomic changes.

Distinct patterns of cytopenias that are distinguishable from standard chemotherapy-associated cytopenias are seen after chimeric antigen receptor T-cell t

Distinct patterns of cytopenias that are distinguishable from standard chemotherapy-associated cytopenias are seen after chimeric antigen receptor T-cell t

Cytomegalovirus (CMV) reactivation occurred in 27% of CMV-seropositive chimeric antigen receptor–modified T-cell immunotherapy (CARTx) recipients within 12

Nature Medicine - In the ALYCANTE trial, second-line treatment with axicabtagene ciloleucel, a CD19-targeting CAR T-cell therapy, resulted in high response rates and durable remissions in patients...

n/European Society for Blood and Marrow Transplantation (EHA/EBMT) guidelines on the management of “immune effector cell-associated hematotoxicity” (ICAHT), we undertook a survey of experienced...

Abstract. Autologous CAR-T cell therapy (CAR-T) has improved outcomes for patients with B-cell malignancies. It is associated with the well-described canon

With 6 chimeric antigen receptor (CAR) T-cell products approved by the US Food and Drug Administration and many more showing promise in clinical trials, th

Background BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side effects that can lengthen...

The CAR-HEMATOTOX risk-stratifies for toxicity and survival in relapsed/refractory MCL.

This retrospective study demonstrates that the obesity paradox applies to patients receiving CAR T-cell therapy and that sarcopenia can exert long-lasting adverse effects on treatment responses. The...

Key Points. The NRM rate estimate after CAR T-cell therapy for large B-cell lymphomas was 5%, with ∼80% of deaths occurring beyond day 28 after infusion.In

multicenter retrospective observational study, we studied the patient-individual journey from CAR-T indication to infusion, baseline features, and survival outcomes in 374 patients treated with...

Key Points. Previous studies showed that fludarabine PK exposure is associated with key outcomes in pediatric patients after tisagenlecleucel.In adults rec

TO THE EDITOR:

Kai Rejeski, MD, LMU Hospital Munich, Munich, Germany, discusses the use of the CAR-HEMATOTOX score to identify patients who are at risk of non-relapse mortality post-chimeric antigen receptor (CAR)...

TO THE EDITOR:

The hematologic toxicity of chimeric antigen receptor (CAR) T-cell therapy is widely recognized, but which patients are at highest risk for major prolonged

Key Points. In normal and malignant human B cells, CD20 mRNA is alternatively spliced to yield 4 5′ untranslated region isoforms, some of which are transla

Background and ObjectivesSecondary CNS involvement in systemic B-cell lymphoma (SCNSL) is difficult to treat and displays dismal clinical outcomes. Chimeric antigen receptor (CAR) T cells emerged as...

PURPOSE Approximately 30%-40% of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) infused with CD19-targeted chimeric antigen receptor (CAR) T cells achieve durable responses....

In this issue of Blood, Rejeski et al, representing an international panel of experts from the European Hematology Association (EHA) and the European Socie